Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Alpha-3 beta-2 nicotinic acetylcholine receptor (α3β2 nAChR) is a heteropentameric ligand-gated ion channel composed of α3 and β2 subunits [1, 2]. While the α3 subunit is predominantly expressed in the peripheral nervous system within autonomic ganglia, where it typically pairs with the β4 subunit, the α3β2 subtype is a significant component of the central nervous system, particularly in hippocampal interneurons [2, 4]. In the hippocampus, these receptors are involved in regulating the synchronous firing of pyramidal cells and modulating the release of various neurotransmitters [2]. The receptor can exist in multiple functional stoichiometries, which exhibit distinct sensitivities to agonists and different rates of desensitization, providing a potential basis for highly selective pharmacological intervention [2, 4]. The α3β2 nAChR is considered a promising therapeutic target for cognitive enhancement and the treatment of neurodevelopmental and neurodegenerative disorders, including Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and autism spectrum disorder [3, 4]. Genetic studies have also linked variations in the α3 subunit to nicotine dependence and alcohol abuse [9]. Pharmacologically, the receptor is activated by agonists like nicotine and varenicline and is potently inhibited by specific toxins such as alpha-conotoxin MII [5]. A major challenge in targeting this receptor is achieving selectivity over the α3β4 subtype found in autonomic ganglia to avoid systemic side effects such as cardiovascular and gastrointestinal distress [2].
The alpha-3 beta-2 nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel that mediates fast excitatory neurotransmission. Upon binding of agonists such as acetylcholine or nicotine, the receptor undergoes a conformational change that opens a central pore, allowing the influx of cations (primarily Na+ and Ca2+) and the efflux of K+. This ion flow results in membrane depolarization and can trigger downstream signaling pathways or modulate the release of other neurotransmitters, particularly in the hippocampus and autonomic ganglia [1, 2, 8].
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-3 beta-2 nicotinic acetylcholine receptor (α3β2 nAChR) (α3β2 nAChR).